

| OMB APPROVAL                                 |           |
|--|-----------|
| OMB Number:                                  | 3235-0287 |
| Estimated average burden hours per response: | 0.5       |

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

|   |   |  |
|---|---|--|
| 1. Name and Address of Reporting Person*<br><u>Chen Bihua</u><br><br>(Last) (First) (Middle)<br><u>C/O CORMORANT ASSET MANAGEMENT, LLC</u><br><u>200 CLARENDON STREET, 52ND FLOOR</u><br><br>(Street)<br><u>BOSTON MA 02116</u><br><br>(City) (State) (Zip) | 2. Issuer Name and Ticker or Trading Symbol<br><u>Erasca, Inc. [ ERAS ]</u> | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)<br><br><input checked="" type="checkbox"/> Director 10% Owner<br><br>Officer (give title below) Other (specify below)                      |
|   | 3. Date of Earliest Transaction (Month/Day/Year)<br><u>12/20/2022</u>       |  |
|   | 4. If Amendment, Date of Original Filed (Month/Day/Year)                    | 6. Individual or Joint/Group Filing (Check Applicable Line)<br><br><input checked="" type="checkbox"/> Form filed by One Reporting Person<br><input type="checkbox"/> Form filed by More than One Reporting Person |

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) |   | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) |            |       | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|------------|-------|---|--|---|
|                                 |                                      |  | Code                           | V | Amount  | (A) or (D) | Price |   |  |   |
| Common Stock                    | 12/13/2022                           |  | P                              |   | 307,692   | A          | \$6.5 | 10,813,246  | I  | See Footnotes <sup>(1)(2)(3)</sup>                    |

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) |   | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) |                 | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|--|-----------------|---|--|--|---|--|
|  |  |                                      |  | Code                           | V |  | Date Exercisable   | Expiration Date |   |  |  |   |  |
| Stock Option (right to buy)                | \$5.808  |                                      |  |                                |   |  | (4)  | 04/11/2031      | Common Stock  | 166,666                                    | 166,666  | D <sup>(5)</sup>  |  |
| Stock Option (right to buy)                | \$5.35   |                                      |  |                                |   |  | 06/22/2023   | 06/21/2032      | Common Stock  | 40,000                                     | 40,000   | D <sup>(5)</sup>  |  |

1. Name and Address of Reporting Person\*  
Chen Bihua  
 (Last) (First) (Middle)  
C/O CORMORANT ASSET MANAGEMENT, LLC  
200 CLARENDON STREET, 52ND FLOOR  
 (Street)  
BOSTON MA 02116  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
Cormorant Asset Management, LP  
 (Last) (First) (Middle)  
200 CLARENDON STREET  
52ND FLOOR  
 (Street)  
BOSTON MA 02116  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
Cormorant Global Healthcare Master Fund, LP

|   |         |          |
|---|---------|----------|
| (Last)  | (First) | (Middle) |
| 200 CLARENDON STREET, 52ND FLOOR                |         |          |
| (Street)  |         |          |
| BOSTON  | MA      | 02116    |
| (City)  |         |          |
| (State)   | (Zip)   |          |
| 1. Name and Address of Reporting Person*        |         |          |
| <u>Cormorant Private Healthcare Fund II, LP</u> |         |          |
| (Last)  |         |          |
| 200 CLARENDON STREET, 52ND FLOOR                |         |          |
| (Street)  |         |          |
| BOSTON  | MA      | 02116    |
| (City)  |         |          |
| (State)   | (Zip)   |          |

**Explanation of Responses:**

- Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Ms. Chen disclaims beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Ms. Chen is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
- Represents (i) 2,986,402 shares of Common Stock held by the Master Fund, (ii) 7,716,444 shares of Common Stock held by Fund II, and (iii) 110,400 shares of Common Stock held by the Account.
- Shares reported herein as purchased on December 9, 2022 were purchased by the Master Fund.
- Stock option grant for 166,666 shares, 41,667 shares of which become exercisable on 3/16/2022 and 124,999 shares of which become exercisable thereafter in equal monthly installments through 3/16/2025.
- Stock options granted to Bihua Chen, in her capacity as a director of the Issuer.

/s/ Bihua Chen 07/22/2021

/s/ CORMORANT ASSET  
MANAGEMENT, LP By:  
Cormorant Asset Management  
GP, LLC, its General Partner,  
By: Bihua Chen, Managing  
Member 07/22/2021

/s/ CORMORANT GLOBAL  
HEALTHCARE MASTER  
FUND, LP, By: Cormorant  
Global Healthcare GP, LLC, its  
General Partner By: Bihua  
Chen, Managing Member 07/22/2021

/s/ CORMORANT PRIVATE  
HEALTHCARE FUND II, LP  
By: Cormorant Private  
Healthcare GP II, LLC, its  
General Partner By: Bihua  
Chen, Managing Member 07/22/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**